 "Centre files petition to transfer FDC cases to SC")
The central government has moved a transfer petition related to the cases where pharmaceutical companies have filed against ban of FDCs or Fixed Dose Combination drugs. Through the petition, the government has sought withdrawal of the pleas pending before high courts of Delhi, Kerala, Karnataka and Madras, so that these can be taken up by the Supreme Court.
In the first batch, cases between Pfizer, Abbott Healthcare, Macleods Pharmaceuticals, All Kerala Chemists Association are expected to come up.
The controversy arose after the central government issued a notification on March 10 pursuant to the Doctor Kokate Committee report banning 344 FDCs, prompting most large pharmaceutical manufacturers including Pfizer, Abbott, GlaxoSmithKline and Cipla to immediately challenge the move in the Delhi High Court.
The petitions pertain to ban on sale of Abbott's Tixylix toddler syrup and Phensedyl cough syrup ,Pfizer's cough syrup 'Corex' ,as well as Macleods' Panderm Plus ointment.
The Health Ministry, through a gazette notification, banned over 300 fixed dose combination drugs, including cough syrups compositions, saying they involve "risk" to humans and safer alternatives were available. The two pharmaceuticals sought quashing of Centre's March 10 notification and urged the court to call the records including the expert committee.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%